PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, 0.1mg/mL [26628-22-8]

Biotium

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, 0.1mg/mL

9

Flow Cytometry, ImmunoFluorescence, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Monoclonal

PDL1/2746

0.1 mg/ml

Other Conjugate

CD274

CD274 molecule

B7 homolog 1; B7-H; B7H1; CD274 antigen; hPD-L1; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL1; PD-L1; programmed cell death 1 ligand 1

Mouse

IgG2b

Programmed cell death 1 ligand 1

PD-L1 (also known as Programmed Death Ligand 1, CD274, and B7-H1) is one of two cell surface ligands that engage the negative regulatory T cell surface receptor PD-1. PD-L1 is a Type I transmembrane protein expressed on the plasma membrane of cells, such as activated macrophages and some tumor cells. Because binding of PD-1 by PD-L1 has a suppressive effect on the immune system, inhibition of the PD-1/PD-L1 pathway is a major strategy of immune-oncology therapies. PD-L1 is upregulated in certain cancers, and blocking PD-1 or PD-L1 can inhibit cancer growth. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Animal

Bovine, Human, Mouse

2°C to 8°C

12352203